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INTRODUCTION: 
COVID-19 has been frequently cited as a condition causing a pro-inflammatory state 
leading to hypercoagulopathy and increased risk for venous thromboembolism. This 
condition has thus prompted prior studies and screening models that utilize D-dimer for 
pulmonary embolism (PE) into question. The limited research to date has failed to 
provide tools or guidance regarding what COVID-19 positive patients should receive 
pulmonary CT angiography screening. This knowledge gap has led to missed diagnoses, 
CT overutilization, and increased morbidity and mortality. 
OBJECTIVE: 
The purpose of this study was to examine the utility of the quantitative D-dimer lab 
marker in a convenience sample of 426 COVID-19 positive patients to assist providers in 
determining the utility of pulmonary CT angiography. 
METHODS: 
The authors conducted a retrospective analysis on all COVID-19 positive patients within 
the Henry Ford Medical System between March 1st, 2020 through April 30th, 2020 who 
received pulmonary CT angiography and had a quantitative D-dimer lab drawn within 24 
hours of CT imaging. 
RESULTS: 
Our sampling criteria yielded a total of n = 426 patients, of whom 347 (81.5%) were 
negative for PE and 79 (18.5%) were positive for PE. The average D-dimer in the negative 
PE group was 2.95 μg./mL. (SD 4.26), significantly different than the 9.15 μg./mL. (SD 
6.80) positive PE group (P < 0.05; 95% CI -7.8, -4.6). Theoretically, applying the 
traditional ≤ 0.5 μg./mL. D-dimer cut-off to our data would yield a sensitivity of 100% and 
specificity of 7.49% for exclusion of PE. Based on these results, the authors would be able 
to increase the D-dimer threshold to < 0.89 μg./mL. to maintain their sensitivity to 100% 
and raise the specificity to 27.95%. Observing a D-dimer cut-off value of ≤ 1.28 μg./mL. 
would reduce sensitivity to 97.47% but increase the specificity to 57.93%. 
CONCLUSIONS: 
These study results support the utilization of alternative D-dimer thresholds to exclude 
PE in COVID-19 patients. Based on these findings, providers may be able to observe 
increased D-dimer cut-off values to reduce unnecessary pulmonary CT angiography 
scans. 
INTRODUCTION 
In late 2019, a new strain of coronavirus known as severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or 
“COVID-19” was discovered.1 The majority of the first 
COVID-19 cases were either asymptomatic or resulted in 
relatively mild disease with a broad range of symptoms. 
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During later 2020, thrombotic complications emerged as 
important sequelae contributing to significant morbidity 
and mortality in COVID-19 patients.2 More patients in-
fected with COVID-19 may now be predisposed to throm-
botic disease such as pulmonary embolism (PE) due to ex-
cessive inflammation, platelet activation, endothelial 
dysfunction, and stasis.3 
In one 2020 US report of over 370,000 symptomatic con-
firmed COVID-19 patients, shortness of breath was cited to 
be present in 29% of cases.4 Similar to COVID-19, PE can 
have a wide range of presenting symptoms but the most 
common being shortness of breath.5 This overlap of symp-
toms and predisposition for thrombotic complications has 
posed a challenge for clinicians to promptly identify PE in 
COVID-19 patients. Rapid confirmation or exclusion of PE 
is vitally important for initiating appropriate therapy with 
anticoagulation. 
Traditionally, the D-dimer lab marker (normally ≤ 0.5 
μg./mL.) has been utilized in conjunction with clinical prob-
ability assessments to rule out PE.6 When elevated, the D-
dimer should prompt further diagnostic imaging to identify 
PE, specifically, pulmonary CT angiography. Despite the in-
creased risk of PE in COVID-19 patients, there remains no 
validation or consensus on D-dimer values and when to ob-
tain pulmonary CT angiography. 
PURPOSE OF STUDY 
The purpose of this retrospective study was to examine the 
utility of quantitative D-dimer lab values in a convenience 
sample of confirmed COVID-19 patients to assist providers 
considering the need for pulmonary CT angiography to con-
firm or exclude PE. 
METHODS 
After IRB project approval was obtained, the authors first 
conducted a retrospective analysis of all confirmed 
COVID-19 patients who received pulmonary CT angiogra-
phy. Patients were further classified as being positive or 
negative for PE. Following this initial electronic health 
record (EHR) data extraction, the authors’ primary endpoint 
was to evaluate the quantitative D-dimer value between 
these two sample subgroups. Additional demographic and 
clinical patient information (e g., age, gender, presence of 
infiltrate on chest X-ray or CT, and mortality) were col-
lected. Infiltrate was defined as an abnormal substance 
within the interstitium or alveoli of the lungs. 
Study data were collected using the EPIC Workbench EHR 
from the Henry Ford Health System. An initial data report 
was generated by the Principal Investigator (GM) on May 
15th, 2020 from all patients who tested positive for 
COVID-19 and received a pulmonary CT angiography during 
their ED visit or inpatient hospitalization. The authors in-
cluded data points spanning from March 1st through April 
30th, 2020. This initially yielded 605 unique cases that were 
reduced to 426 patients after applying our inclusion and ex-
clusion criteria. 
Chart reviews by authors GM and AE of each eligible pa-
tient were utilized to ensure each patient was positive for 
COVID-19, had received pulmonary CT angiography, and 
had a documented D-dimer lab value obtained within 24 
hours of the CT being performed. If a sample patient had 
received multiple (i.e., routinely ordered) D-dimer values, 
the D-dimer values that were drawn closest to the time the 
CT were completed was in analyses. In contrast, individu-
als who did not have a quantitative D-dimer within 24 hours 
were excluded. This approach was utilized by the authors to 
account for daily D-dimer values typically found in patients. 
Furthermore, charts which were marked privacy re-
stricted by EPIC (e g., prisoners and healthcare system em-
ployees) were excluded to maintain confidentiality. Finally, 
patients who underwent pulmonary CT angiography which 
were determined to be inadequate (i.e., unable to exclude 
PE) by the radiologist were excluded. Inadequate CT’s were 
most commonly attributed to poor image quality due to mo-
tion artifact (i.e., patient movement) and/or contrast bo-
lus timing leading to poor contrast enhancement. However, 
CTs that were read as having a “limited evaluation” and still 
able to exclude pulmonary embolism to any degree were in-
cluded. 
DATA ANALYSES 
All analyses were performed by author RJ using Minitab Sta-
tistical Software (State College, PA) or Vassarstats.net on-
line calculator.7,8 Categorical data were summarized as 
counts and percentages, and continuous data were sum-
marized as means with corresponding standard deviations. 
Between-group mean differences were compared by calcu-
lating t-tests for independent measures. Categorical data 
were compared using the chi-square test for association. 
Throughout this study, a p-value ≤ 0.05 (two-tailed) was 
considered statistically significant. 
Sensitivities and specificities of D-dimer lab values for 
PE exclusion were calculated using different thresholds. 
Thresholds were chosen based on the distribution of our 
sample population data, with the overall goal of attempting 
to attain a PE sensitivity of 100%. 
RESULTS 
SAMPLE CHARACTERISTICS 
Our sample population was gathered from the Henry Ford 
Health System between March 1st through April 30th, 2020. 
After initial data extractions, a total sample of n = 426 
(70.4%) patients were included in our analytic sample from 
an initial total of 605. The gender distribution of our sample 
included 209 males (49.1%) and 217 females (50.9%). The 
mean age in years for our sample population was 61.62 
(SD 16.56) with a range of 19 to 99, further depicted in 
histogram form with superimposed normal distributional 
curve. (Figure 1). 
MAIN RESULTS 
Of the total 426 sample patients, 347 (81.5%) were negative 
for PE and 79 (18.5%) were positive for PE. The average D-
dimer in the “negative for PE” group was 2.95 μg./mL. (SD 
4.26) and significantly different compared to 9.15 μg/mL 
(SD 6.80) in the “positive for PE” group (P < 0.05) (Table 1). 
Applying the traditional ≤ 0.5 μg./mL. D-dimer threshold 
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Table 1. Main results comparing negative and positive pulmonary embolism subgroups. 
Group N (%) Average D-dimer (SD) (μg./mL.) 
Negative for PE 347 (81.5) 2.95 (4.26) 
Positive for PE 79 (18.5) 9.15 (6.80) 
PE = Pulmonary Embolism 
Table 2. Sensitivity and specificity for pulmonary embolism at specific D-dimer thresholds 
within our sample population. Includes counts of PE present or absent. 
D-dimer Threshold PE Present PE Absent Sensitivity Specificity 
≤0.5 μg./mL. 
>0.5 μg./mL. 79 321 
100% 7.49% 
≤0.5 μg./mL. 0 26 
<0.89 μg./mL. 
≥0.89 μg./mL. 79 250 
100% 27.95% 
<0.89 μg./mL. 0 97 
≤1.28 μg./mL. 
>1.28 μg./mL. 77 146 
97.46% 57.93% 
≤1.28 μg./mL. 2 201 
PE = Pulmonary Embolism 
against our study data yielded a sensitivity for excluding 
PE to be 100% and specificity of 7.49% (Table 2). The au-
thors were able to increase the D-dimer threshold to < 0.89 
μg./mL. to maintain a sensitivity of 100% but raise the 
specificity to 27.95% (Table 2). Additional analyses of a cut-
off value of ≤ 1.28 μg./mL. reduced the sensitivity to 97.47% 
but increased the specificity to 57.93% (Table 2). Figure 2 
depicts the distribution of D-dimer values between the PE 
negative and PE positive sample subgroups. 
SECONDARY FINDINGS 
Additional data were analyzed to draw further conclusions 
and note trends that may clinically assist providers. Regard-
ing demographics, the mean age of the PE positive group 
was 61.3 years old (SD 15.6) versus the PE negative group 
which was 61.7 years old (SD 16.8). This difference was not 
statistically significant (P = 0.86). Furthermore, of the 79 
patients with PE, 42 (53.2%) were male while 37 (46.8%) 
were female (P = 0.42). 
During the peak of COVID-19 at our institution, it be-
came apparent that many of these patients had initial chest 
X-rays that demonstrated “multifocal pneumonia” but were 
later found to be positive for PE. In this study, those pa-
tients who received a chest X-ray (CXR) (N=407), 321 
(78.9%) were identified of having infiltrate in X-ray reports. 
Those who received pulmonary CT angiography (N=426), 
390 (91.6%) were identified to have infiltrate in reports. Al-
though not formally analyzed, these data support the con-
clusion that infiltrates identified on imaging does not ex-
clude PE in COVID-19 patients. 
The authors also compared mortality rates within the an-
alytic sample. Overall, 68 (16.0%) sample patients were de-
ceased at the time of data collection (May-July 2020). The 
Figure 1. Age distribution of sample 
percentage of patients who died in the “positive for PE” 
group (N=12, 15.2%) versus “negative for PE” group (N=56, 
16.1%) showed no significant chi square test difference (P = 
0.84), although this may have been attributable to the small 
sample size. 
STUDY LIMITATIONS 
Some typical measurement limitations in COVID-19 study 
designs include a wide variability in sensitivity of the na-
sopharyngeal swabs, largely dependent on: a) the types and 
quality of specimens obtained,9,10 b) duration of illness at 
the time of their testing,11,12 and c) the specific assay that 
was used.13,14 This could have led to false negatives which, 
in turn, would have resulted in missed data points. During 
the study, we did not take into account certain health condi-
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tions (e g., pregnancy, a history of clotting disorder or can-
cer, ambulatory status, trauma), anticoagulation status, or 
other co-morbidities such as end stage renal disease and 
other forms of venous thromboembolism or arterial occlu-
sion which may have affected our results.15 
Neither did our sample include individuals who under-
went alternative diagnostic modalities for venous throm-
boembolism. As previously mentioned, we also excluded 
cases in which CT images were read as “inadequate” due 
to motion artifact (i.e., patient movement) and problematic 
timing of contrast bolus. 
DISCUSSION 
COVID-19 has been cited as causing a pro-inflammatory 
state which can lead to increased risk for venous throm-
boembolism.16 Based on these results and those from ear-
lier studies, thrombotic complications such as PE are fre-
quently identified in COVID-19 patients and can lead to 
increased morbidity and mortality if not promptly diag-
nosed.2 The overlap of symptoms has been particularly 
challenging in determining whom to perform pulmonary 
CT angiography on. In these analyses, utilization of the 
D-dimer lab marker may be one tool to assist providers 
in determining the need for pulmonary CT angiography in 
COVID-19 patients. 
As previously mentioned, the utility of D-dimer lab val-
ues to rule out PE has apparently only been validated in 
non-COVID-19 patients to date.6 The traditional D-dimer 
value of ≤ 0.5 μg./mL. serves as an important tool to rule 
out PE in patients with a low and intermediate probability 
for PE. In our n = 426 sample, we were able to maintain 
a sensitivity of 100% to rule out PE observing a D-dimer 
threshold of < 0.89 μg./mL while increasing our specificity 
to 27.95% from 7.49% when compared to the traditional D-
dimer threshold. Despite our increase in specificity, the D-
dimer still primarily retains its purpose as a negative pre-
dictive tool due to the number of aforementioned comorbid 
conditions that can raise D-dimer levels.15 
When we observed an increased “< 0.89 ug./mL” D-dimer 
threshold, we considerably reduced (i.e., approx.. 97 
(22.7%) the number of evidently unnecessary pulmonary CT 
angiography scan orders. In comparison, theoretically ap-
plying the traditional D-dimer threshold of ≤ 0.5 μg./mL. to 
our study only reduced CT scans by 6.1% (i.e., 26 CT scans). 
This has significant implications for patient safety, cost uti-
lization, and more appropriate use of hospital resources. 
During our study, we found a significant difference in av-
erage D-dimer value in the PE positive group compared to 
the PE negative group: 9.15 μg./mL. versus 2.95 μg./mL., re-
spectively. Significantly elevated serum thrombogenic pro-
teins such as the D-dimer have also been associated with 
increased mortality in COVID-19 patients.17 Although the 
Figure 2. Distribution of D-dimer values between 
the PE negative and PE positive subgroups. 
D-dimer serves primarily as a negative predictive tool, 
providers should be vigilant when significantly elevated D-
dimer values are obtained in COVID-19 patients. Although 
other forms of venous thromboembolism and arterial oc-
clusion were not formally addressed during our study, 
providers may consider further development of lower D-
dimer thresholds for certain patient subgroups receiving 
additional diagnostic studies.15 
CONCLUSIONS 
Although thrombotic complications such as PE have been 
frequently associated with COVID-19, few tools currently 
exist to identify patients requiring pulmonary CT angiog-
raphy. Our study findings indicate an increased D-dimer 
threshold can be reasonably used to rule out PE and elimi-
nate unnecessary pulmonary CT angiography scans. 
Prompt diagnosis of PE will generally lead to appropriate 
therapies and potentially better patient outcomes. Further 
studies focusing on alternative diagnostic modalities with 
significantly elevated D-dimer cases are certainly necessary 
given the associated increased mortality. Further studies 
considering how empiric anticoagulation may be warranted 
in clinically unstable COVID-19 patients with elevated D-
dimer values are needed. 
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